You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

CARDENE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Cardene patents expire, and when can generic versions of Cardene launch?

Cardene is a drug marketed by Chiesi and is included in three NDAs. There are six patents protecting this drug.

The generic ingredient in CARDENE is nicardipine hydrochloride. There are eleven drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the nicardipine hydrochloride profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Cardene

A generic version of CARDENE was approved as nicardipine hydrochloride by ANI PHARMS on October 28th, 1996.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for CARDENE?
  • What are the global sales for CARDENE?
  • What is Average Wholesale Price for CARDENE?
Summary for CARDENE
Drug patent expirations by year for CARDENE
Drug Prices for CARDENE

See drug prices for CARDENE

Recent Clinical Trials for CARDENE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Boston Medical CenterPhase 4
National Institute of Neurological Disorders and Stroke (NINDS)Phase 2
University of CincinnatiPhase 2

See all CARDENE clinical trials

US Patents and Regulatory Information for CARDENE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Chiesi CARDENE SR nicardipine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020005-003 Feb 21, 1992 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Chiesi CARDENE nicardipine hydrochloride CAPSULE;ORAL 019488-001 Dec 21, 1988 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Chiesi CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER nicardipine hydrochloride INJECTABLE;INTRAVENOUS 019734-002 Jul 31, 2008 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Chiesi CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER nicardipine hydrochloride INJECTABLE;INTRAVENOUS 019734-005 Nov 7, 2008 DISCN Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for CARDENE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Chiesi CARDENE nicardipine hydrochloride CAPSULE;ORAL 019488-001 Dec 21, 1988 ⤷  Sign Up ⤷  Sign Up
Chiesi CARDENE nicardipine hydrochloride INJECTABLE;INJECTION 019734-001 Jan 30, 1992 ⤷  Sign Up ⤷  Sign Up
Chiesi CARDENE nicardipine hydrochloride INJECTABLE;INJECTION 019734-001 Jan 30, 1992 ⤷  Sign Up ⤷  Sign Up
Chiesi CARDENE nicardipine hydrochloride INJECTABLE;INJECTION 019734-001 Jan 30, 1992 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for CARDENE

See the table below for patents covering CARDENE around the world.

Country Patent Number Title Estimated Expiration
Mexico 2008013407 COMPOSICIONES DE BOLO IV PREMEZCLADAS, LISTAS PARA USO Y METODOS DE USO. (PRE-MIXED, READY-TO-USE IV BOLUS COMPOSITIONS AND METHODS OF USE.) ⤷  Sign Up
Switzerland 613192 Process for the preparation of novel 1,4-dihydropyridine derivatives ⤷  Sign Up
Canada 1240930 PROCEDE DE PRODUCTION D'UNE INJECTION D'HYDROCHLORURE DE NICARDIPINE (PROCESS FOR PRODUCING AN INJECTION OF NICARDIPINE HYDROCHLORIDE) ⤷  Sign Up
Brazil PI0709617 composição farmacêutica, e, métodos para tratar elevações agudas de pressão sangüìnea em um indivìduo humano, para induzir a hipotensão em um indivìduo humano, e para produzir uma composição farmacêutica para administração intravenosa ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.